Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02229084). This is a study registration, not published results. Lead sponsor: University of Arkansas. Recruitment status: COMPLETED. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 58 participants (ACTUAL). Conditions: Breast Cancer, Breast Neoplasms. Interventions: BIOLOGICAL: P10s-PADRE/ MONTANIDE™ ISA 51 VG; DRUG: Doxorubicin; DRUG: Cyclophosphamide; DRUG: Docetaxel. Primary outcome measures: Identify a Feasible Schedule of Vaccination Relative to SoC Neoadjuvant Chemotherapy When the Chemovax Are Administered Concurrently. , At the time of definitive surgery (4-8 weeks after chemo, which is between Week 22 and Week 25); Determine the pCR Rate , At the time of definitive surgery (4-8 weeks after chemo, which is between Week 22 and Week 25). Brief summary: The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III estrogen-receptor (ER)-positive, HER2-negative breast cancer.